Akari is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, and leukotriene system, for the treatment of rare and orphan diseases with unmet need. We believe that blocking early mediators of inflammation will prevent initiation and continual amplification of the processes that cause certain diseases.
Nomacopan is a recombinant small protein (16,740 Da) that acts on complement component-C5, preventing release of C5a and formation of C5b–9 (also known as the membrane attack complex, or MAC), and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response.
Nomacopan is currently being clinically evaluated in four indications:
- bullous pemphigoid (BP), , a severe blistering skin disease
- atopic keratoconjunctivitis (AKC), a sight threatening surface of the eye condition
- thrombotic microangiopathys (TMA) including including atypical hemolytic uremic syndrome (aHUS) and hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT TMA)
- paroxysmal nocturnal hemoglobinuria (PNH).
Akari believes that the dual action of nomacopan on both C5 and LTB4 may be beneficial in AKC, BP, and aHUS. Akari is also developing other tick derived proteins, including longer acting versions.
Nomacopan is a highly soluble and stable biological molecule, and independently binds to both C5 and LTB4. This novel dual binding enables targeting of two distinct and separate disease categories based on their underlying etiology.